LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 238

Search options

  1. Article: Improving biochemical markers for disorders of N-glycosylation.

    Freeze, Hudson H

    Annals of translational medicine

    2019  Volume 7, Issue Suppl 6, Page(s) S176

    Language English
    Publishing date 2019-09-05
    Publishing country China
    Document type Editorial ; Comment
    ZDB-ID 2893931-1
    ISSN 2305-5847 ; 2305-5839
    ISSN (online) 2305-5847
    ISSN 2305-5839
    DOI 10.21037/atm.2019.07.79
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: XMEN: welcome to the glycosphere.

    Freeze, Hudson H

    The Journal of clinical investigation

    2019  Volume 130, Issue 1, Page(s) 80–82

    Abstract: XMEN (X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia) is a complex primary immunological deficiency caused by mutations in MAGT1, a putative magnesium transporter. In this issue of the JCI, Ravell et al. greatly expand the ... ...

    Abstract XMEN (X-linked immunodeficiency with magnesium defect, EBV infection, and neoplasia) is a complex primary immunological deficiency caused by mutations in MAGT1, a putative magnesium transporter. In this issue of the JCI, Ravell et al. greatly expand the clinical picture. The authors investigated patients' mutations and symptoms and reported distinguishing immunophenotypes. They also showed that MAGT1 is required for N-glycosylation of key T cell and NK cell receptors that can account for some of the clinical features. Notably, transfection of the affected lymphocytes with MAGT1 mRNA restored both N-glycosylation and receptor function. Now we can add XMEN to the ever-growing family of congenital disorders of glycosylation (CDG).
    MeSH term(s) Cation Transport Proteins ; Epstein-Barr Virus Infections ; Glycosylation ; Humans ; Magnesium ; X-Linked Combined Immunodeficiency Diseases
    Chemical Substances Cation Transport Proteins ; Magnesium (I38ZP9992A)
    Language English
    Publishing date 2019-12-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 3067-3
    ISSN 1558-8238 ; 0021-9738
    ISSN (online) 1558-8238
    ISSN 0021-9738
    DOI 10.1172/JCI134240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: CDG or not CDG.

    Freeze, Hudson H / Jaeken, Jaak / Matthijs, Gert

    Journal of inherited metabolic disease

    2022  Volume 45, Issue 3, Page(s) 383–385

    MeSH term(s) Congenital Disorders of Glycosylation/diagnosis ; Congenital Disorders of Glycosylation/genetics ; Glycosylation ; Humans
    Language English
    Publishing date 2022-04-01
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 438341-2
    ISSN 1573-2665 ; 0141-8955
    ISSN (online) 1573-2665
    ISSN 0141-8955
    DOI 10.1002/jimd.12498
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Clinical and biochemical footprints of congenital disorders of glycosylation: Proposed nosology.

    Ng, Bobby G / Freeze, Hudson H / Himmelreich, Nastassja / Blau, Nenad / Ferreira, Carlos R

    Molecular genetics and metabolism

    2024  Volume 142, Issue 1, Page(s) 108476

    Abstract: We have identified 200 congenital disorders of glycosylation (CDG) caused by 189 different gene defects and have proposed a classification system for CDG based on the mode of action. This classification includes 8 categories: 1. Disorders of ... ...

    Abstract We have identified 200 congenital disorders of glycosylation (CDG) caused by 189 different gene defects and have proposed a classification system for CDG based on the mode of action. This classification includes 8 categories: 1. Disorders of monosaccharide synthesis and interconversion, 2. Disorders of nucleotide sugar synthesis and transport, 3. Disorders of N-linked protein glycosylation, 4. Disorders of O-linked protein glycosylation, 5. Disorders of lipid glycosylation, 6. Disorders of vesicular trafficking, 7. Disorders of multiple glycosylation pathways and 8. Disorders of glycoprotein/glycan degradation. Additionally, using information from IEMbase, we have described the clinical involvement of 19 organs and systems, as well as essential laboratory investigations for each type of CDG. Neurological, dysmorphic, skeletal, and ocular manifestations were the most prevalent, occurring in 81%, 56%, 53%, and 46% of CDG, respectively. This was followed by digestive, cardiovascular, dermatological, endocrine, and hematological symptoms (17-34%). Immunological, genitourinary, respiratory, psychiatric, and renal symptoms were less frequently reported (8-12%), with hair and dental abnormalities present in only 4-7% of CDG. The information provided in this study, including our proposed classification system for CDG, may be beneficial for healthcare providers caring for individuals with metabolic conditions associated with CDG.
    Language English
    Publishing date 2024-04-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1418518-0
    ISSN 1096-7206 ; 1096-7192
    ISSN (online) 1096-7206
    ISSN 1096-7192
    DOI 10.1016/j.ymgme.2024.108476
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Deficient glycan extension and endoplasmic reticulum stresses in ALG3-CDG.

    Daniel, Earnest J P / Edmondson, Andrew C / Argon, Yair / Alsharhan, Hind / Lam, Christina / Freeze, Hudson H / He, Miao

    Journal of inherited metabolic disease

    2024  

    Abstract: ALG3-CDG is a rare congenital disorder of glycosylation (CDG) with a clinical phenotype that includes neurological manifestations, transaminitis, and frequent infections. The ALG3 enzyme catalyzes the first step of endoplasmic reticulum (ER) luminal ... ...

    Abstract ALG3-CDG is a rare congenital disorder of glycosylation (CDG) with a clinical phenotype that includes neurological manifestations, transaminitis, and frequent infections. The ALG3 enzyme catalyzes the first step of endoplasmic reticulum (ER) luminal glycan extension by adding mannose from Dol-P-Man to Dol-PP-Man
    Language English
    Publishing date 2024-04-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 438341-2
    ISSN 1573-2665 ; 0141-8955
    ISSN (online) 1573-2665
    ISSN 0141-8955
    DOI 10.1002/jimd.12739
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Perhaps a wee bit of sugar would help.

    Freeze, Hudson H

    Nature genetics

    2016  Volume 48, Issue 7, Page(s) 705–707

    Abstract: A new genetic disorder might be treatable through consumption of a simple sugar, but the relative contributions of endogenous and dietary sources are mostly unknown. It's time to change that. ...

    Abstract A new genetic disorder might be treatable through consumption of a simple sugar, but the relative contributions of endogenous and dietary sources are mostly unknown. It's time to change that.
    Language English
    Publishing date 2016-06-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1108734-1
    ISSN 1546-1718 ; 1061-4036
    ISSN (online) 1546-1718
    ISSN 1061-4036
    DOI 10.1038/ng.3600
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Is X-linked, infantile onset ALG13-related developmental and epileptic encephalopathy a congenital disorder of glycosylation?

    Berry, Gerard T / Freeze, Hudson H / Morava, Eva

    Epilepsia

    2021  Volume 62, Issue 2, Page(s) 335–336

    MeSH term(s) Glycosylation ; Humans ; N-Acetylglucosaminyltransferases ; Spasms, Infantile/genetics
    Chemical Substances ALG13 protein, human (EC 2.4.1.-) ; N-Acetylglucosaminyltransferases (EC 2.4.1.-)
    Language English
    Publishing date 2021-02-11
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 216382-2
    ISSN 1528-1167 ; 0013-9580
    ISSN (online) 1528-1167
    ISSN 0013-9580
    DOI 10.1111/epi.16817
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Chemical Therapies for Congenital Disorders of Glycosylation.

    Sosicka, Paulina / Ng, Bobby G / Freeze, Hudson H

    ACS chemical biology

    2021  Volume 17, Issue 11, Page(s) 2962–2971

    Abstract: Congenital disorders of glycosylation (CDG) are ultrarare, genetically and clinically heterogeneous metabolic disorders. Although the number of identified CDG is growing rapidly, there are few therapeutic options. Most treatments involve dietary ... ...

    Abstract Congenital disorders of glycosylation (CDG) are ultrarare, genetically and clinically heterogeneous metabolic disorders. Although the number of identified CDG is growing rapidly, there are few therapeutic options. Most treatments involve dietary supplementation with monosaccharides or other precursors. These approaches are relatively safe, but in many cases, the molecular and biochemical underpinnings are incomplete. Recent studies demonstrate that yeast, worm, fly, and zebrafish models of CDG are powerful tools in screening repurposed drugs, ushering a new avenue to search for novel therapeutic options. Here we present a perspective on compounds that are currently in use for CDG treatment or have a potential to be applied as therapeutics in the near future.
    MeSH term(s) Animals ; Congenital Disorders of Glycosylation/drug therapy ; Congenital Disorders of Glycosylation/diagnosis ; Congenital Disorders of Glycosylation/metabolism ; Zebrafish ; Glycosylation
    Language English
    Publishing date 2021-11-17
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 1554-8937
    ISSN (online) 1554-8937
    DOI 10.1021/acschembio.1c00601
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: GLUT1 is a highly efficient L-fucose transporter.

    Ng, Bobby G / Sosicka, Paulina / Xia, Zhijie / Freeze, Hudson H

    The Journal of biological chemistry

    2022  Volume 299, Issue 1, Page(s) 102738

    Abstract: Understanding L-fucose metabolism is important because it is used as a therapy for several congenital disorders of glycosylation. Exogenous L-fucose can be activated and incorporated directly into multiple N- and O-glycans via the fucose salvage/ ... ...

    Abstract Understanding L-fucose metabolism is important because it is used as a therapy for several congenital disorders of glycosylation. Exogenous L-fucose can be activated and incorporated directly into multiple N- and O-glycans via the fucose salvage/recycling pathway. However, unlike for other monosaccharides, no mammalian L-fucose transporter has been identified. Here, we functionally screened nearly 140 annotated transporters and identified GLUT1 (SLC2A1) as an L-fucose transporter. We confirmed this assignment using multiple approaches to alter GLUT1 function, including chemical inhibition, siRNA knockdown, and gene KO. Collectively, all methods demonstrate that GLUT1 contributes significantly to L-fucose uptake and its utilization at low micromolar levels. Surprisingly, millimolar levels of D-glucose do not compete with L-fucose uptake. We also show macropinocytosis, but not other endocytic pathways, can contribute to L-fucose uptake and utilization. In conclusion, we determined that GLUT1 functions as the previously missing transporter component in mammalian L-fucose metabolism.
    MeSH term(s) Biological Transport ; Fucose/metabolism ; Glucose ; Glucose Transporter Type 1/genetics ; Glucose Transporter Type 1/metabolism ; Membrane Transport Proteins/genetics ; Membrane Transport Proteins/metabolism
    Chemical Substances Fucose (28RYY2IV3F) ; Glucose (IY9XDZ35W2) ; Glucose Transporter Type 1 ; Membrane Transport Proteins
    Language English
    Publishing date 2022-11-22
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 2997-x
    ISSN 1083-351X ; 0021-9258
    ISSN (online) 1083-351X
    ISSN 0021-9258
    DOI 10.1016/j.jbc.2022.102738
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Perspectives on Glycosylation and Its Congenital Disorders.

    Ng, Bobby G / Freeze, Hudson H

    Trends in genetics : TIG

    2018  Volume 34, Issue 6, Page(s) 466–476

    Abstract: Congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic disorders that result from abnormal protein or lipid glycosylation. They are often difficult to clinically diagnose because they broadly affect many organs and ... ...

    Abstract Congenital disorders of glycosylation (CDG) are a rapidly expanding group of metabolic disorders that result from abnormal protein or lipid glycosylation. They are often difficult to clinically diagnose because they broadly affect many organs and functions and lack clinical uniformity. However, recent technological advances in next-generation sequencing have revealed a treasure trove of new genetic disorders, expanded the knowledge of known disorders, and showed a critical role in infectious diseases. More comprehensive genetic tools specifically tailored for mammalian cell-based models have revealed a critical role for glycosylation in pathogen-host interactions, while also identifying new CDG susceptibility genes. We highlight recent advancements that have resulted in a better understanding of human glycosylation disorders, perspectives for potential future therapies, and mysteries for which we continue to seek new insights and solutions.
    MeSH term(s) Congenital Disorders of Glycosylation/complications ; Congenital Disorders of Glycosylation/genetics ; Congenital Disorders of Glycosylation/metabolism ; Congenital Disorders of Glycosylation/pathology ; Glycosylation ; High-Throughput Nucleotide Sequencing ; Host-Pathogen Interactions/genetics ; Humans ; Infection/complications ; Infection/genetics ; Infection/metabolism ; Infection/pathology ; Lipid Metabolism
    Language English
    Publishing date 2018-03-29
    Publishing country England
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 619240-3
    ISSN 1362-4555 ; 0168-9525 ; 0168-9479
    ISSN (online) 1362-4555
    ISSN 0168-9525 ; 0168-9479
    DOI 10.1016/j.tig.2018.03.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top